Oklo stock tumbles as Financial Times scrutinizes valuation
SOUTH JORDAN, Utah - Merit Medical Systems, Inc. (NASDAQ:MMSI), a medical device manufacturer with a market capitalization of $4.93 billion and a "GOOD" financial health rating according to InvestingPro, announced Wednesday that its SCOUT Radar Localization system has been used in 750,000 patients worldwide for breast cancer treatment.
The milestone coincides with Breast Cancer Awareness Month and highlights the growth of the company’s wire-free non-radioactive localization technology. According to the company, the SCOUT system helps physicians surgically remove abnormal breast tissue with precision of +/- 1 mm. The company’s innovation has contributed to its solid 10.11% revenue growth over the last twelve months.
The radar localization technology works by implanting a reflector approximately the size of a grain of rice, allowing surgeons to target affected tissue more precisely. The system can be used in various treatment scenarios, including placement in breast tissue and lymph nodes, and before or after chemotherapy.
Merit Medical recently expanded its portfolio with SCOUT MD, which provides four distinct reflector shapes to enable more precise tumor margin mapping and localization of multiple lesions.
The company reports that SCOUT is currently used in 50 countries, with more than 500 cases performed daily and 10,000 monthly. Over 1,100 facilities worldwide have adopted the system as their preferred method of wire-free localization.
"We’re delighted to see the positive impact SCOUT has on patients’ lives," said Fred Lampropoulos, Merit Medical’s Chairman and Chief Executive Officer, in the press release statement.
The National Breast Cancer Foundation estimates that more than 300,000 new cases of invasive breast cancer will be diagnosed in women in the United States this year.
Merit Medical Systems, founded in 1987, develops and manufactures medical devices used in various medical procedures and employs approximately 7,300 people worldwide.
In other recent news, Merit Medical Systems reported second-quarter 2025 earnings that exceeded market expectations. The company achieved an earnings per share of $1.01, surpassing the anticipated $0.85, and generated revenue of $382.5 million, which was higher than the projected $374.18 million. Merit Medical’s organic revenue growth improved to 6.7% year-over-year in the second quarter, up from 6.0% in the first quarter of 2025. Following these strong results, Needham maintained its Buy rating for Merit Medical, with a price target of $108.00. Additionally, Merit Medical announced that its Embosphere Microspheres received European Union approval for use in genicular artery embolization to treat knee osteoarthritis. This approval allows for a minimally invasive procedure aimed at reducing blood flow to the inflamed synovium in the knee joint, potentially offering pain relief and improved mobility for patients. These developments highlight Merit Medical’s ongoing progress in both financial performance and product innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.